FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases
- PMID: 28525362
- DOI: 10.1515/hmbci-2017-0002
FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases
Abstract
Fibroblast growth factor 21 (FGF21) analogs and FGF21 receptor agonists (FGF21RAs) that mimic FGF21 ligand activity constitute the new "FGF21-class" of anti-obesity and anti-diabetic molecules that improve insulin sensitivity, ameliorate hepatosteatosis and promote weight loss. The metabolic actions of FGF21-class proteins in obese mice are attributed to stimulation of brown fat thermogenesis and increased secretion of adiponectin. The therapeutic utility of this class of molecules is being actively investigated in clinical trials for the treatment of type 2 diabetes and non-alcoholic steatohepatitis (NASH). This review is focused on various FGF21-class molecules, their molecular designs and the preclinical and clinical activities. These molecules include modified FGF21 as well as agonistic antibodies against the receptor for FGF21, namely the complex of FGF receptor 1 (FGFR1) and the obligatory coreceptor βKlotho (KLB). In addition, a novel approach to increase endogenous FGF21 activity by inhibiting the FGF21-degrading protease fibroblast activation protein (FAP) is discussed.
Keywords: NAFLD; monoclonal antibodies; obesity; therapeutics; type 2 diabetes.
Similar articles
-
Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex.EBioMedicine. 2015 May 30;2(7):730-43. doi: 10.1016/j.ebiom.2015.05.028. eCollection 2015 Jul. EBioMedicine. 2015. PMID: 26288846 Free PMC article.
-
FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes.Mol Metab. 2017 Nov;6(11):1454-1467. doi: 10.1016/j.molmet.2017.09.003. Epub 2017 Sep 18. Mol Metab. 2017. PMID: 29107292 Free PMC article.
-
Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.Sci Transl Med. 2012 Nov 28;4(162):162ra153. doi: 10.1126/scitranslmed.3004690. Sci Transl Med. 2012. PMID: 23197570
-
Nutritional regulation of fibroblast growth factor 21: from macronutrients to bioactive dietary compounds.Horm Mol Biol Clin Investig. 2016 Sep 1;30(1):/j/hmbci.2017.30.issue-1/hmbci-2016-0034/hmbci-2016-0034.xml. doi: 10.1515/hmbci-2016-0034. Horm Mol Biol Clin Investig. 2016. PMID: 27583468 Review.
-
Fibroblast growth factor-21, energy balance and obesity.Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:66-73. doi: 10.1016/j.mce.2015.09.018. Epub 2015 Sep 26. Mol Cell Endocrinol. 2015. PMID: 26415590 Review.
Cited by
-
New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis.J Clin Transl Hepatol. 2021 Feb 28;9(1):51-59. doi: 10.14218/JCTH.2020.00057. Epub 2020 Nov 27. J Clin Transl Hepatol. 2021. PMID: 33604255 Free PMC article. Review.
-
Fibroblast growth factor 21 deficiency aggravates obesity-induced hypothalamic inflammation and impairs thermogenic response.Inflamm Res. 2019 May;68(5):351-358. doi: 10.1007/s00011-019-01222-2. Epub 2019 Mar 12. Inflamm Res. 2019. PMID: 30863887
-
Restricting Branched-Chain Amino Acids within a High-Fat Diet Prevents Obesity.Metabolites. 2022 Apr 7;12(4):334. doi: 10.3390/metabo12040334. Metabolites. 2022. PMID: 35448521 Free PMC article.
-
A single combination gene therapy treats multiple age-related diseases.Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23505-23511. doi: 10.1073/pnas.1910073116. Epub 2019 Nov 4. Proc Natl Acad Sci U S A. 2019. PMID: 31685628 Free PMC article.
-
Adipocyte epigenetic alterations and potential therapeutic targets in transgenerationally inherited lean and obese phenotypes following ancestral exposures.Adipocyte. 2019 Dec;8(1):362-378. doi: 10.1080/21623945.2019.1693747. Adipocyte. 2019. PMID: 31755359 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
